10 years of revenue, profit, cash flow and balance-sheet history through FY2025, from SEC filings — with a computed, factual read of the trend. Updated Overview →
| FY | Revenue | Net income | Gross M | Op M | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|
| 2025 | $8M | -$465M | 86.0% | -6714.8% | -$384M | — | $102M |
| 2024 | $1M | -$298M | 100.0% | -32613.5% | -$234M | — | $265M |
| 2023 | $4M | -$215M | 100.0% | -5547.2% | -$173M | — | $55M |
| 2022 | $0 | -$164M | — | — | -$117M | — | $33M |
| 2021 | $0 | -$108M | — | — | -$89M | — | $201M |
| 2020 | $71000 | -$74M | 0.0% | -105567.6% | -$62M | — | $93M |
| 2019 | $1M | -$50M | 0.0% | -4512.3% | -$47M | — | $40M |
| 2018 | $2M | -$27M | 0.0% | -1182.5% | -$21M | — | $45M |
| 2017 | $2M | -$9M | 0.0% | -446.3% | -$10M | — | $14M |
| 2016 | $589000 | -$6M | 0.0% | -1026.1% | -$6M | — | — |
| Quarter | Revenue | Net income | Gross M | Op M | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|
| Mar '26 | $11M | -$128M | 98.1% | -1307.8% | -$126M | — | $114M |
| Dec '25 | $6M | -$123M | 0.0% | -2169.6% | -$93M | — | $102M |
| Sep '25 | $143000 | -$130M | 0.0% | -99710.5% | -$112M | — | $111M |
| Jun '25 | $1M | -$116M | 0.0% | -12523.0% | -$89M | — | $54M |
| Mar '25 | $361000 | -$97M | 100.0% | -30860.1% | -$90M | — | $95M |
| Dec '24 | $0 | -$81M | — | — | -$68M | — | $265M |
| Sep '24 | $0 | -$77M | — | — | -$63M | — | $317M |
| Jun '24 | $399000 | -$74M | 0.0% | -20747.6% | -$49M | — | $302M |
| Mar '24 | $640000 | -$67M | 0.0% | -11488.9% | -$54M | — | $396M |
| Dec '23 | — | -$60M | — | — | -$39M | — | $55M |
| Sep '23 | $346000 | -$57M | 0.0% | -17045.4% | -$45M | — | $143M |
| Jun '23 | $988000 | -$51M | 0.0% | -5363.9% | -$46M | — | $40M |
| Mar '23 | $3M | -$46M | 0.0% | -1790.9% | -$41M | — | $41M |
| Dec '22 | -$4M | -$45M | 0.0% | 1180.6% | -$35M | — | $33M |
| Sep '22 | $458000 | -$42M | 0.0% | -9487.8% | -$39M | — | $31M |
| Jun '22 | $439000 | -$42M | 0.0% | -9805.2% | -$29M | — | $62M |
| Mar '22 | $3M | -$35M | 0.0% | -1080.4% | -$14M | — | $146M |
| Dec '21 | $0 | -$31M | — | — | -$23M | — | $201M |
| Sep '21 | $0 | -$28M | — | — | -$26M | — | $162M |
| Jun '21 | — | -$26M | — | — | -$20M | — | $179M |
How the market has priced CRNX against its own fundamentals since 2023-03 — each month-end's share price set against the most recent annual filing, so the multiple moves as price runs ahead of (or behind) earnings. Split-adjusted.
Over the past 5 years, Crinetics Pharmaceuticals, Inc.'s revenue has grown 155.3% per year. These are computed facts, not advice.
As of FY2025, Crinetics Pharmaceuticals, Inc. reported — of total debt against $102M of cash.
In FY2025, gross margin was 86.0%, operating margin -6714.8%, and net margin -6046.0%.
All figures are extracted from the company’s SEC EDGAR/XBRL filings — 10-K annual reports and 10-Q quarterly reports (use the Annual / Quarterly toggle). Quarterly figures are derived from the as-filed statements (year-to-date amounts are differenced into discrete quarters). Growth rates and ratios are computed by tradmap; nothing here is investment advice.
Source: SEC EDGAR / XBRL (10-K + 10-Q filings) · prices EOD (Databento), corporate-action-adjusted · growth rates, valuation multiples & ratios computed by tradmap. Valuation uses each month-end price against the latest annual filing. Informational only — not investment advice.